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The article, entitled “Impact of Breast Surgery in Primary 
Metastasized Breast Cancer Outcomes of the Prospective 
Randomized Phase III ABCSG-28 POSYTIVE Trial”, 
published in the Annals of Surgery (1), is the third to 
study to prospectively evaluate the prognostic efficacy of 
breast surgery in patients with metastases (Table 1). This 
trial evaluated breast surgery for newly diagnosed de novo 
stage IV breast cancer patients with no history of systemic 
therapy. After providing informed consent, patients were 
allocated to arm A (surgery consisting of either standard 
breast-conserving surgery or mastectomy including axillary 
staging and systemic therapy) or to arm B (systemic therapy 
without surgery). The patients were stratified according 
to grading, receptor status, HER2 status, metastasis 
location (visceral vs. bone-only metastases) and planned 
first-line therapy. As systemic therapy, chemotherapy, 
anti-HER2 therapy, or anti-hormone therapy was 
administered according to local standards, with regimens 
including modern effective drugs. The primary endpoint 
was overall survival (OS) and the authors reported that they 
could not demonstrate a prognostic benefit for primary 
tumor resection. Additionally, they reported worsening 
of the outcomes of the patients with distant metastasis. 
The time to distant progression in the surgery arm was 
shorter (though not significantly) than that in the no-
surgery arm (HR 0.598, 95% CI, 0.343–1.043; P=0.0668). 
These results were very similar to those of the first report 
on a prospective trial from India (2) but different from the 
results of many retrospective reports (3). In our view, the 
limitation of systemic therapies is one of the reasons for this 
discrepancy. In the Indian trial, the patients did not receive 
systemic therapies according to breast cancer subtypes. 
Anti-HER2 targeted therapies were not used for patients 
with HER2-positive subtype, and very few patients with 
ER-positive tumors received hormone therapy. In addition, 
the discontinuation of effective systemic therapy after 
randomization might result in a poorer outcome, especially 
distant progression free survival, in the patients with 
primary tumor resection. However, the patients received 
modern and continuous systemic therapy in this ABCSG 
trial and the results were similar to those of prior trials. 
Given these results, it appears that stage IV breast cancer 
patients should not undergo primary tumor surgery.
However, there is an important problem that needs to 
be addressed. Statistically, the authors planned for a control 
arm, systemic therapy alone: median survival 24 months, 
experimental arm, surgery plus systemic therapy: median 
survival 36 months; HR of 0.666, alpha level 5%, power 
80%, drop-out rate 5%, requiring 254 patients (127 in 
each treatment arm) to be enrolled in order to observe 192 
events. However, due to poor recruitment, the study was 
stopped prematurely after 5 years when only 90 patients had 
been enrolled, 45 in each arm. The statistical power was 
thus very low. Moreover, the median survival of the control 
arm was 54.8 months, which was longer than specified in 
the protocol plan, such that they would have needed more 
patients and a longer follow-up period than in their initial 
plan to detect a 6-month advantage of surgery. 
The MF07-01 trial from Turkey evaluated the prognostic 
effects of breast surgery as the primary treatment 
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and found that breast surgery might prolong OS (4). 
However, it was not possible to confirm that surgery 
achieves an 18% improvement of the 3-year survival rate 
according to their preplanned analysis. On the other hand, 
a longer follow-up study showed statistically significant 
improvement in median survival (HR 0.66; 95% CI, 
0.49–0.88; P=0.005) (The authors did not plan this analysis 
as part of their initial protocol).
We know that the most significant treatment to improve 
the prognosis of metastatic breast cancer patients is the 
effective systemic therapy. Systemically administered 
drugs clearly prolong survival. Local therapy, including 
surgery and/or radiation, is one of the choices of additional 
treatment. Our aim should be to indicate the most 
effective treatment strategies for individual cancer patients, 
employing drugs, surgery and radiation, alone or in various 
combinations. The goals for them are to prolong their 
survival and to control symptoms. We want to answer the 
questions “Who would benefit from breast surgery?” and 
“When should patients receive surgery?”.
The Japan Clinical Oncology Group (JCOG 1017, 
UMIN000005586) (5) and Eastern Clinical Oncology 
Group (ECOG 2108, NCT01242800) are completing 
the recruitment of recruiting and following patients for a 
prospective trial. These trials have enough patients to allow 
statistically meaningful analysis of their hypothesis, and 
patients received the modern standard systemic therapy, 
including molecular target therapies, available both before 
and after randomization. These trials will resolve current 
controversies and provide many eagerly awaited answers. 
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Table 1 The prospective trials which evaluate the prognostic efficacy of primary tumor resection
Trial group Trial number Accrual period (situation) N Initial therapy
India (Tata Memorial Hospital) NTC00193778 2005–2012 (completed) 350 Systemic 
JCOG UMIN000005586 (JCOG1017) 2011–2018 (completed) 500/410→ 570/407 Systemic 
ECOG NCT01242800 (ECOG2108) 2011–2015 (completed) 880/660→ 368/258 Systemic 
Turkey NCT00557986 (MF07-01) 2008–2012 (completed) 281 Surgery
ABCSG NCT01015625 (ABCSG 28) 2010–2015 (early stopped) 256→ 90 Surgery
